Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 EDITAS MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaw ...

Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2022 Results Conference Call February 22, 2023 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Gilmore O’Neill - Chief Executive Officer Michelle Robertson - Chief Financial Officer Baisong Mei - Chief Medical Officer Conference Call Participants Samantha Semenkow - Citi Dae Gon Ha - Stifel Phil Nadeau - Cowen & Company Rick Bienkowski - Cantor Fitzgerald Jay Olson - Oppenheimer Brian Cheng - JP Morgan Luca Issi - RBC Capital Markets Greg Harrison - B ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 EDITAS MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware ( ...

Editas Medicine, Inc. (NASDAQ:EDIT) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 7:30 PM ET Company Participants Gilmore O’Neill - CEO Baisong Mei - Chief Medical Officer Michelle Robertson - CFO Conference Call Participants Brian Cheng - JPMorgan Gilmore O’Neill Okay. Good afternoon, everyone. I am being told to progress, to maintain the clock. And I also understand that I am the last speaker between you and the bar. So even more important that I get this right and follow instructions. Br ...

Industry/Company Involved * **Company**: Editas Medicine, Inc. (NASDAQ:EDIT) * **Industry**: Biotechnology, Gene Editing, Hematology Key Points and Arguments 1. **EDIT-301 Clinical Update**: Editas Medicine presented early clinical data from the RUBY study evaluating EDIT-301 for severe sickle cell disease (SCD) [6][7]. 2. **Safety Profile**: The initial safety profile of EDIT-301 was consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant. Both dose participants showed successful engraftment and stopped red blood cell transfusions without any vaso-occlusive events (VOEs) [6]. 3. **Efficacy**: The first patient achieved a fetal hemoglobin (HBF) level of 45.4% and a total hemoglobin of 16.4 g/dL five months after EDIT-301 treatment. This suggests clinical proof of concept and potential for robust clinical benefit in SCD patients [7][8]. 4. **Mechanism of Action**: EDIT-301 uses a novel CRISPR nuclease, AsCas12a, to target the promoter region of the gamma globin gene 1 and 2, increasing fetal hemoglobin expression and mimicking the natural mechanism of hereditary persistence of fetal hemoglobin [12]. 5. **RUBY Study**: The RUBY study is a Phase 1/2 study designed to evaluate the safety, tolerability, and efficacy of EDIT-301 in severe SCD patients. The study will recruit up to 40 patients aged 18-50 years with a history of at least two VOEs per year [13]. 6. **Future Plans**: Editas Medicine plans to provide more data from the RUBY study, including data from additional patients, in the middle of 2023 [19]. Other Important Points * **Regulatory Pathway**: Editas Medicine is actively engaging with regulators and expects to have greater clarity on the required patient data set and follow-up for a BLA submission in the coming year [36]. * **Alternative Conditioning Therapies**: Editas Medicine is exploring alternative conditioning regimens beyond busulfan to reduce treatment burden for patients and treatment sites [38]. * **Clinical Differentiation**: Editas Medicine believes that its unique therapeutic strategy, including the use of AsCas12a and targeting the gamma globin promoter, could lead to significant differentiation from other SCD therapies [31]. * **Patient Engagement**: Editas Medicine values engagement with investigators, clinicians, and patient communities and believes that patient education and understanding of the science behind EDIT-301 are crucial [82].

Editas Medicine, Inc. (NASDAQ:EDIT) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Gilmore O’Neill - Chief Executive Officer Baisong Mei - Chief Medical Officer Mark Shearman - Chief Scientific Officer Michelle Robertson - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Greg Harrison - Bank of America Joon Lee - Truist Securities Dae Gon Ha - Stifel Phil Nadeau - Cowen & Co. Jay Olson - Oppenheimer Joel Beatty - ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 EDITAS MEDICINE, INC. (Exact name of registrant as specified in its charter) D ...

Summary of Editas Medicine, Inc. Conference Call Company Overview - **Company**: Editas Medicine, Inc. (NASDAQ:EDIT) - **Date**: September 12, 2022 - **Participants**: - Gilmore O'Neill - President and CEO - Mark Shearman - Executive VP and Chief Scientific Officer - Baisong Mei - Senior VP and Chief Medical Officer - Michelle Robertson - Chief Financial Officer Key Industry Insights - **Gene Editing Landscape**: The call discussed the competitive landscape of gene editing technologies, particularly focusing on CRISPR, base editing, and prime editing. Editas utilizes the AsCas12a enzyme, which is engineered for higher fidelity and efficiency compared to the Cas9 enzyme used by many competitors [5][6][9]. Core Technology and Differentiation - **AsCas12a Enzyme**: Editas employs the AsCas12a enzyme for its gene editing programs, which is noted for its high on-target activity and specificity. This enzyme allows for precise control over gene editing, reducing potential off-target effects [5][7][10]. - **Guide RNA**: The company uses a smaller guide RNA (41 mer) compared to the larger guide RNA (90-100 mer) used in Cas9 technologies, enhancing the quality and purity of the editing process [9][10]. - **Clinical Applications**: The AsCas12a enzyme is particularly important in Editas' cell therapy approaches, such as the EDIT-301 program for sickle cell disease, where high control over editing is crucial [7][10]. Clinical Programs - **BRILLIANCE Study**: This is a Phase 1 interventional study targeting LCA10, a rare genetic disease. The study aims to assess safety and efficacy, focusing on identifying patient segments likely to respond to treatment [24][25][28]. - **Endpoints**: The study will evaluate various endpoints, including visual acuity, quality of life, and physiological parameters, to determine treatment effectiveness [26][29][31]. - **Data Release**: Data from the study is expected to be shared in October/November 2022, with a focus on identifying patient populations that show a meaningful benefit [28][31]. Intellectual Property and Monetization - **IP Position**: Editas holds exclusive licenses from the Broad Institute for Cas9-related IP, which positions the company favorably in the gene editing market. The company is confident in its IP standing following favorable reviews by the PTAB and federal appeals court [18][19][20]. - **Monetization Strategy**: The company is considering monetizing its IP as a potential revenue stream, particularly for therapeutic applications involving Cas9 [18][19]. Financial Position - **Cash Reserves**: As of Q2 2022, Editas reported over $500 million in cash, which is expected to sustain operations into 2024 while the company explores additional financing opportunities [53]. Conclusion - Editas Medicine is positioned as a leader in the gene editing space, leveraging its proprietary AsCas12a technology to differentiate itself from competitors. The company is focused on advancing its clinical programs while maintaining a strong IP position and financial health.

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 EDITAS MEDICINE, INC. (Exact name of registrant as specified in its charter) Tradin ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 EDITAS MEDICINE, INC. (Exact name of registrant as specified in its charter) Tradi ...